Secondary Skin Involvement in Classic Hodgkin Lymphoma: Results of an International Collaborative Cutaneous Lymphoma Working Group Study of 25 Patients

Author(s):  
Alejandro A. Gru ◽  
Carlos E. Bacchi ◽  
Melissa Pulitzer ◽  
Govind Baghat ◽  
Werner Kempf ◽  
...  
Life ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1069
Author(s):  
Magda Zanelli ◽  
Stefano Ricci ◽  
Francesca Sanguedolce ◽  
Andrea Palicelli ◽  
Enrico Farnetti ◽  
...  

Mycosis fungoides and nodal classic Hodgkin lymphoma (cHL) have been reported to occur concurrently or sequentially in the same patient. A long-lasting mycosis fungoides more often precedes the onset of nodal cHL, although few cases of nodal cHL followed by mycosis fungoides have been observed. Skin involvement is a rare manifestation of cHL that may be observed in the setting of advanced disease. The decrease in skin involvement in cHL is mainly due to the improved therapeutic strategies. The concurrent presence of mycosis fungoides and cutaneous localization of classic Hodgkin lymphoma represents a very uncommon event, with only two cases reported so far. Herein, we describe the case of a 71-year-old man, with a history of recurrent nodal cHL, who developed MF and, subsequently, the cutaneous localization of cHL. The clinicopathological features of the two diseases are described focusing on the main differential diagnoses to be taken into consideration, and a review of the literature is performed.


2020 ◽  
Vol 154 (Supplement_1) ◽  
pp. S110-S110
Author(s):  
B Mai ◽  
J Huddin ◽  
Z Hu

Abstract Casestudy A 52-year-old female presented with night sweats, chills, anorexia, and weight loss. Computed tomography and positron emission tomography showed a soft tissue infiltration in the anterior mediastinum and hypermetabolic bilateral supraclavicular, mediastinal, right hilar, and left internal mammary lymph nodes. An anterior mediastinal mass resection and thymectomy was subsequently performed. Results Sections of the mediastinal mass showed Hodgkin/Reed-Sternberg cells (HRS) admixed with small lymphocytes, histiocytes, plasma cells, and eosinophils. The HRS cells are positive for CD30, CD15, and MUM1, faintly positive for PAX5, and negative for CD20, CD45, CD79a, and BCL6. The morphology and immunophenotype is diagnostic of nodular sclerosis classic Hodgkin lymphoma (CHL). Sections of the thymectomy specimen showed similar morphology, however, in an area that represents 10-20% of the specimen, there are nodular and diffuse lymphoid infiltrates consisting of small lymphocytes, histiocytes, and large atypical cells. The large atypical cells are positive for CD20, CD23, CD30, CD45, CD79a, BCL2, BCL6, MUM-1, and PAX5, and negative for CD1a, CD3, CD57, and Cyclin D1. The background small CD3-positive lymphocytes form a rosette around most of the large atypical cells. CD21 and CD23 stains highlight residual follicular structures. In situ hybridization for EBV-encoded RNA (EBER) is negative. The presence of residual follicular meshwork with an immunophenotype of large B cell lymphoma supports a diagnosis of a gray zone lymphoma (GZL). Overall, CHL is involving 80-90% and GZL is involving 10-20% of the thymic tissue. The patient was subsequently placed on ABVD chemotherapy and achieved remission. Conclusion An accurate diagnosis of GZL is challenging. GZL is a rare type of lymphoma with morphological features between CHL and diffuse large B-cell lymphoma (DLBCL). It is even rarer to encounter a CHL concurrently present with a GZL. The optimal therapeutic approach for cases with concurrent lymphoma diagnosed with CHL and GZL needs further investigation.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ombretta Annibali ◽  
Antonella Bianchi ◽  
Alba Grifoni ◽  
Valeria Tomarchio ◽  
Mariantonietta Tafuri ◽  
...  

AbstractClinical use of immune-checkpoints inhibitors (anti PD-1/PD-L1) resulted very effective for the treatment of relapsed/refractory classic Hodgkin Lymphoma (CHL). Recently, T cell Ig and ITIM domains (TIGIT) has been recognized as an immune checkpoint receptor able to negatively regulate T cell functions. Herein, we investigated the expression of TIGIT in CHL microenvironment in order to find a potential new target for inhibitor therapy. TIGIT, PD-1 and PD-L1 expression was evaluated in 34 consecutive patients with CHL. TIGIT expression in T lymphocytes surrounding Hodgkin Reed-Sternberg (HRS) cells was observed in 19/34 patients (56%), of which 11 (58%) had advanced stages. In 16/19 (84%) cases, TIGIT+ peritumoral T lymphocytes showed also PD-1 expression. All 15 TIGIT− patients had PD-L1 expression in HRS cells (100%) while among 19 TIGIT+ patients, 11 (58%) were PD-L1+ and 8 (42%) were PD-L1−. Using a new scoring system for TIGIT immunoreactivity, all TIGIT+ cases with higher score (4/19) were PD-L1−. Our results confirm co-expression of TIGIT and PD-1 in peritumoral T lymphocytes. Of relevance, we demonstrated a mutually exclusive expression of TIGIT and PD-L1 using new TIGIT scoring system able to identify this immunocheckpoints’ modulation. These results pave the way to new therapeutic strategies for relapsed/refractory CHL.


2010 ◽  
Vol 5 (3) ◽  
pp. 135-139 ◽  
Author(s):  
Yasuhiro Oki ◽  
Anas Younes

2016 ◽  
Vol 22 (6) ◽  
pp. 341-343
Author(s):  
Ayyappa S. Duba ◽  
Sharon Dowell ◽  
Mercedes Quiñones ◽  
Tammey J. Naab ◽  
Lekidelu Taddesse-Heath ◽  
...  

2012 ◽  
Vol 167 (1) ◽  
pp. 174-179 ◽  
Author(s):  
Y. Peñate ◽  
B. Hernández-Machín ◽  
L.I. Pérez-Méndez ◽  
F. Santiago ◽  
B. Rosales ◽  
...  

2018 ◽  
Vol 13 (2) ◽  
pp. 15
Author(s):  
L. D. S. De Silva ◽  
S. Wijetunge ◽  
T. Jayamaha

2020 ◽  
Vol 5 (1) ◽  
pp. 011-019
Author(s):  
Taylor Kelley ◽  
Ullery Sally ◽  
Papiez Joe ◽  
Thomason Ron ◽  
Lee Ron

Sign in / Sign up

Export Citation Format

Share Document